Form 4: Relay Therapeutics Director Linda Hill Reports Stock Option Grant

Director Linda Hill reports receiving a stock option for 102,225 shares of Relay Therapeutics common stock on June 3, 2024.

Summary

• Linda Hill, a director of Relay Therapeutics, Inc. (RLAY), filed a Form 4 on June 5, 2024, reporting a transaction.
• On June 3, 2024, Hill was granted a stock option to purchase 102,225 shares of RLAY common stock at an exercise price of $6.79.
• The option vests in full on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders following the grant date.
• Following the reported transaction, Hill directly owns options for 102,225 shares of Relay Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports a standard transaction.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule of one year is fairly typical, although some companies may use longer or shorter vesting periods.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates